HighTower Advisors
AMRX icon

HighTower Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

HighTower Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-93,386
Closed -$1.16M – 3810
2026
Q1 		$1.16M Buy
93,386
+4,379
+5% +$58.8K ﹤0.01% 2083
2025
Q4 		$1.12M Buy
+89,007
New +$1.02M ﹤0.01% 2036
2024
Q4 		– Sell
-12,192
Closed -$103K – 3815
2024
Q3 		$103K Sell
12,192
-1,011
-8% -$7.91K ﹤0.01% 3306
2024
Q2 		$82K Buy
+13,203
New +$83.8K ﹤0.01% 3244

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

HighTower Advisors's AMRX Position: Q2 2026 in Review

HighTower Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 93,386 shares — an estimated $1.16M sold.

HighTower Advisors first reported a position in AMRX in Q2 2024 and held it in 4 quarters. The position peaked at $1.16M in Q1 2026. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • HighTower Advisors reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HighTower Advisors sold 93,386 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.16M.
  • HighTower Advisors first reported a position in Amneal Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • HighTower Advisors's Amneal Pharmaceuticals position peaked at $1.16M in Q1 2026.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.